A team led by Mervyn Singer, Professor of Intensive Care Medicine at University College London, and Dr Roman Lukaszewski, Chief Diagnostic Officer at the Defence Science & Technology Laboratory (Dstl) of the UK Ministry of Defence, has just published the results of a pioneering sepsis study.

The publication: "Presymptomatic diagnosis of postoperative infection and sepsis using gene expression signatures" in the journal Intensive Care Medicine, represents the culmination of a 20+ year discovery program. This pioneering work highlights the potential for host response biomarker signatures to identify infection and/or sepsis up to 3 days in advance of clinical recognition, with accuracy up to 90%.

The underlying Dstl host-response technology is being developed by Presymptom Health under license from Ploughshare and the Ministry of Defence. Presymptom is currently conducting a multi-site UK NHS clinical trial (PRECISION) to validate its portfolio of genomic and protein-based tests.

Dr Iain Miller, CEO of Presymptom Health commented:
"Presymptom congratulates Professor Singer, Dr Lukaszewski and their clinical and research colleagues on this important publication. We look forward to continuing the development of this important work and helping mitigate a clinical syndrome which claims 11 Million lives annually".

About Presymptom Health

Presymptom Health is a pioneering medtech company focused on development diagnostic tests and predictive software to detect illnesses earlier to help save lives. Established in 2019, it was founded to exploit a ground-breaking innovation to detect sepsis in patients up to three days before symptoms appear. Presymptom Heath is developing a clinical diagnostic test portfolio which will include tests for use at both point-of-care and within central laboratory settings.

- Email: info@presymptom.com
- Website: www.presymptom.com